Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C.

Golden-Mason L, Bambha KM, Cheng L, Howell CD, Taylor MW, Clark PJ, Afdhal N, Rosen HR; Virahep-C Study Group.

Hepatology. 2011 Nov;54(5):1559-69. doi: 10.1002/hep.24556. Epub 2011 Aug 24.

2.

Association of NKG2A with treatment for chronic hepatitis C virus infection.

Harrison RJ, Ettorre A, Little AM, Khakoo SI.

Clin Exp Immunol. 2010 Aug;161(2):306-14. doi: 10.1111/j.1365-2249.2010.04169.x. Epub 2010 Jun 9.

3.

IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.

Suppiah V, Gaudieri S, Armstrong NJ, O'Connor KS, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Dore GJ, Irving WL, Powell E, Hellard M, Riordan S, Matthews G, Sheridan D, Nattermann J, Smedile A, Müller T, Hammond E, Dunn D, Negro F, Bochud PY, Mallal S, Ahlenstiel G, Stewart GJ, George J, Booth DR; International Hepatitis C Genetics Consortium (IHCGC).

PLoS Med. 2011 Sep;8(9):e1001092. doi: 10.1371/journal.pmed.1001092. Epub 2011 Sep 13.

4.

Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C.

Ahlenstiel G, Edlich B, Hogdal LJ, Rotman Y, Noureddin M, Feld JJ, Holz LE, Titerence RH, Liang TJ, Rehermann B.

Gastroenterology. 2011 Oct;141(4):1231-9, 1239.e1-2. doi: 10.1053/j.gastro.2011.06.069. Epub 2011 Jul 7.

5.

Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.

Domagalski K, Pawłowska M, Tretyn A, Halota W, Pilarczyk M, Smukalska E, Linkowska K, Grzybowski T.

Eur J Clin Microbiol Infect Dis. 2013 Jun;32(6):745-54. doi: 10.1007/s10096-012-1799-z. Epub 2013 Jan 13.

6.

Relationship between the genetic variation in interleukin 28B and response to antiviral therapy in patients with chronic hepatitis C.

Xie JQ, Guo XY, Zhang XH, Lin BL, Xie DY, Gao ZL, Wang GS, Zhao ZX.

Chin Med J (Engl). 2012 Jul;125(13):2334-8.

7.

Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes.

Honda M, Shirasaki T, Shimakami T, Sakai A, Horii R, Arai K, Yamashita T, Sakai Y, Yamashita T, Okada H, Murai K, Nakamura M, Mizukoshi E, Kaneko S.

Hepatology. 2014 Mar;59(3):828-38. doi: 10.1002/hep.26788. Epub 2014 Jan 27.

PMID:
24311440
8.

Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C.

Bitetto D, Fattovich G, Fabris C, Ceriani E, Falleti E, Fornasiere E, Pasino M, Ieluzzi D, Cussigh A, Cmet S, Pirisi M, Toniutto P.

Hepatology. 2011 Apr;53(4):1118-26. doi: 10.1002/hep.24201.

PMID:
21480318
9.
10.

Factors that predict response of patients with hepatitis C virus infection to boceprevir.

Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR; SPRINT-2 and RESPOND-2 Investigators.

Gastroenterology. 2012 Sep;143(3):608-18.e1-5. doi: 10.1053/j.gastro.2012.05.011. Epub 2012 May 21.

PMID:
22626609
11.

Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis.

Shi KQ, Liu WY, Lin XF, Fan YC, Chen YP, Zheng MH.

Gene. 2012 Oct 1;507(1):27-35. doi: 10.1016/j.gene.2012.07.026. Epub 2012 Jul 25.

PMID:
22842190
12.

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.

Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, McHutchison JG.

Gastroenterology. 2010 Sep;139(3):821-7, 827.e1. doi: 10.1053/j.gastro.2010.05.079. Epub 2010 Jun 2.

PMID:
20621700
13.

Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients.

Edlich B, Ahlenstiel G, Zabaleta Azpiroz A, Stoltzfus J, Noureddin M, Serti E, Feld JJ, Liang TJ, Rotman Y, Rehermann B.

Hepatology. 2012 Jan;55(1):39-48. doi: 10.1002/hep.24628. Epub 2011 Nov 14.

14.

Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.

De Nicola S, Aghemo A, Rumi MG, Galmozzi E, Valenti L, Soffredini R, De Francesco R, Prati GM, D'Ambrosio R, Cheroni C, Donato MF, Colombo M.

Hepatology. 2012 Feb;55(2):336-42. doi: 10.1002/hep.24683. Epub 2012 Jan 3.

PMID:
21932415
15.

Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin.

Huang CF, Yeh ML, Hsieh MH, Hsieh MY, Lin ZY, Chen SC, Wang LY, Huang JF, Juo SH, Lin YC, Dai CY, Chuang WL, Yu ML.

J Gastroenterol Hepatol. 2013 Sep;28(9):1515-20. doi: 10.1111/jgh.12211.

PMID:
23560893
16.

The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon α treatment.

Pembroke T, Christian A, Jones E, Hills RK, Wang EC, Gallimore AM, Godkin A.

Gut. 2014 Mar;63(3):515-24. doi: 10.1136/gutjnl-2013-304472. Epub 2013 May 11.

17.

Lack of killer immunoglobulin-like receptor 2DS2 (KIR2DS2) and KIR2DL2 is associated with poor responses to therapy of recurrent hepatitis C virus in liver transplant recipients.

Askar M, Avery R, Corey R, Lopez R, Thomas D, Pidwell D, Eghtesad B, Miller C, Fung J, Zein NN.

Liver Transpl. 2009 Nov;15(11):1557-63. doi: 10.1002/lt.21878.

18.

Single-nucleotide polymorphisms of IL-10 and IL-28B as predictors of the response of IFN therapy in HCV genotype 4-infected children.

Shaker OG, Nassar YH, Nour ZA, El Raziky M.

J Pediatr Gastroenterol Nutr. 2013 Aug;57(2):155-60. doi: 10.1097/MPG.0b013e31828febf0.

PMID:
23880623
19.

IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B.

Lampertico P, Viganò M, Cheroni C, Facchetti F, Invernizzi F, Valveri V, Soffredini R, Abrignani S, De Francesco R, Colombo M.

Hepatology. 2013 Mar;57(3):890-6. doi: 10.1002/hep.25749. Epub 2012 Dec 20.

PMID:
22473858
20.

Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.

Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR.

Aliment Pharmacol Ther. 2012 Jul;36(2):91-103. doi: 10.1111/j.1365-2036.2012.05131.x. Epub 2012 May 16.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk